Identification of mutation in LKB1 as a predictive biomarker for sensitivity to TOR kinase inhibitors

摘要

A TOR kinase inhibitor for use in a method of treating non-small cell carcinoma of the lung, cervical cancer, or Peutz-Jeghers syndrome, in which the method comprises administering the TOR kinase inhibitor to a patient who has non-small cell lung carcinoma, cancer of the cervix or Peutz-Jeghers syndrome characterized by a loss of or mutation in the LKB1 gene or protein, compared to the wild type, in which the TOR kinase inhibitor is 7- ( 6- (2-hydroxypropan-2-yl) pyridin-3-yl) -1- (trans-4-methoxycyclohexyl) - 3,4-dihydropyrazino [2,3-b] pyrazin-2 (1H) -one or a salt, clathrate, solvate, stereoisomer or tautomer of this pharmaceutically acceptable.